AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05683275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
Study NCT06492720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) treatment
Description: The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
Study NCT06249984 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04523792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLOCADE
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Study NCT06018116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT06249984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test
Study NCT06428149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midline interproximal soft-tissue incision
Description: Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
Study NCT06428149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marginal approach by palatal incision
Description: First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.
Study NCT06428149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical technique
Description: The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
Study NCT06249984 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test
Study NCT06249984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff
Study NCT05539794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle and physical exercise
Description: the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions.
Study NCT06249984 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff
Study NCT05336097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pathways to Empowerment
Description: Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
Study NCT06249984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06249984 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05348850 — intervention group
Intervention type: DEVICE
Intervention: Tensiomayography (TMG)
Description: Quadriceps muscle contractile properties will be assessed using tensiomayography
Study NCT05849376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergent Multi-Class Imitation Training
Description: Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in applied behavior analysis therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
Study NCT05849376 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emergent Multi-Class Imitation Training
Description: Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in applied behavior analysis therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
Study NCT05500846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Visual Ice Cryoablation System
Description: Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
Study NCT05920096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specialist nurse-led multi-component smoking cessation intervention
Description: Aims to:~* inform participants on the association between smoking and diabetic complications;~* motivate and encourage smokers to quit;~* support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting.
Study NCT05920096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)
Description: A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
Study NCT05327530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study NCT05327530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study NCT05327530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6223
Description: Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study NCT05327530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine 400mg/d
Description: Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide 20mg/d
Description: Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil 2000mg/d
Description: Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hydroxychloroquine 400mg/d
Description: Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Leflunomide 20mg/d
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of Leflunomide 20mg/d
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Mycophenolate mofetil 2000mg/d
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Study NCT05113004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of Mycophenolate mofetil 2000mg/d
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
Study NCT04538352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Medication for type 2 diabetes management
Study NCT04538352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Medication for type 2 diabetes management
Study NCT04538352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Medication for type 2 diabetes management (rapid-acting)
Study NCT06005506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber
Description: Moradyn active prebiotic fiber product
Study NCT06005506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber
Description: Fibregum non-active fiber product
Study NCT06005506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Defense Plus probiotic complex
Study NCT06005506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Defense Plus probiotic complex
Study NCT04665544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.
Description: The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques.
Study NCT05114889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BSI-045B
Description: BSI-045B will be administered weekly, subcutaneously
Study NCT05191329 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TPQue Greek version, NEI-VFQ-25 Greek version
Description: Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
Study NCT06560034 — intervention group
Intervention type: DEVICE
Intervention: VicorderCS
Description: 1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis
Study NCT06348888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral
Study NCT06348888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule, 100 mg, oral.
Study NCT06348888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Tablet, 100 mg, 200mg and 300mg, oral.
Study NCT05462080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ceraxis product
Description: All patients will have their symptoms evaluated using the Ceraxis product
Study NCT06292975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Vigorous intensity aerobic interval exercise
Description: 7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
Study NCT04808284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation
Description: A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
Study NCT04808284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation
Description: A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
Study NCT05209243 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT (all metastatic lesions)
Study NCT05209243 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD OF CARE
Description: ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
Study NCT05209243 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STANDARD OF CARE
Description: ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
Study NCT05164276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position
Description: Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
Study NCT04808284 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct-current stimulation
Description: A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
Study NCT06086691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training with Caffeine
Description: The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions.
Study NCT06086691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training with Caffeine
Description: The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions.
Study NCT04432337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The role of the activation of the NLRP3 inflammasome after cardiac surgery
Description: Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery